穿琥宁注射液治疗病毒性肺炎有效性与安全性Meta分析

Efficacy and Safety of Potassium Dehydroandrogrpholide Succinate Injection for Treating Viral Pneumonia: a Meta-Analysis

目的系统评价穿琥宁注射液治疗病毒性肺炎的有效性及安全性。方法计算机检索Pub Med,EMbase,The Cochrane Library(2017年8期),中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普网(VIP)和万方数据库(Wan Fang Data)、中国临床试验注册中心(www.chictr.org.cn)。搜集穿琥宁注射液治疗病毒性肺炎的随机对照试验,检索时间自建库截至2017年8月。由2位研究人员独立进行文献筛选、数据提取和质量评价后,采用Rev Man 5.3软件进行Meta分析。结果共纳入10个随机对照试验,包括1 653例患者。Meta分析结果显示,小儿患者[RR=1.19,95%CI(1.07,1.33),P=0.001]和成人患者[RR=1.45,95%CI(1.28,1.63),P<0.000 01]应用穿琥宁注射液的有效率均高于对照组;小儿患者的退热时间[MD=-1.11,95%CI(-2.18,-0.04),P=0.04],止咳时间[MD=-1.68,95%CI(-2.48,-0.89),P<0.000 1],罗音消失时间[MD=-1.75,95%CI(-2.24,-1.25),P<0.000 01]和平均住院时间[MD=-2.68,95%CI(-4.08,-1.28),P=0.000 2],穿琥宁注射液组均短于对照组(P<0.05)。结论当前证据表明,穿琥宁注射液治疗病毒性肺炎相较常规药物有一定优势,能显著缩短总住院时间及症状消失时间。

Objective To systematically review the efficacy and safety of Potassium Dehydroandrogrpholide Succinate Injection for treating viral pneumonia. Methods We searched Pub Med,EMbase,The Cochrane Library（ Issue 8,2017）,CBM,CNKI,VIP and Wan Fang Data and the China Clinical Trials Registry（ www. chictr. org. cn） to collect randomized controlled trials（ RCTs） of Potassium Dehydroandrogrpholide Succinate Injection for the patients with viral pneumonia from inception to August 2017. Two reviewers independently screened literature,extracted data and assessed the quality,then,Meta-analysis was performed by Rev Man 5. 3 software.Results A total of 10 studies involving 1 653 patients were included. The results of Meta-analysis showed that： the effective rates of using Potassium Dehydroandrograpolide Succinate Injection in pediatric patients [ RR = 1. 19,95% CI（ 1. 07,1. 33）,P = 0. 001 ] and adult patients [ RR = 1. 45,95% CI（ 1. 28,1. 63）,P 0. 000 01 ] in the Potassium Dehydroandrograpolide Succinate Injection group were higher than those in the control group. The fever clearance time [ MD =-1. 11,95% CI（-2. 18,-0. 04）,P = 0. 04 ],cough relieving time[ MD =-1. 68,95 % CI（-2. 48,-0. 89）,P 0. 000 1 ],rales disappeared time [ MD =-1. 75,95 % CI（-2. 24,-1. 25）,P 0. 000 01 ] and the average hospitalization time [ MD =-2. 68,95% CI（-4. 08,-1. 28）,P = 0. 000 2 ] in the Potassium Dehydroandrograpolide Succinate Injection group were significantly shorter than those in the control group（ P 0. 05）. Conclusion The current evidences show that Potassium Dehydroandrograpolide Succinate Injection in the treatment of viral pneumonia has certain advantages compared with conventional medicine,it can significantly shorten the hospitalization time and the symptoms disappearance time.